The immune system and cancer evasion strategies: therapeutic concepts

The Immune Microenvironment: A Major Player in Human Cancers

(2017) W.H. Fridman et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways

(2015) A Nabeshima et al.   BRITISH JOURNAL OF CANCER

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Bispecific antibodies

(2015) Roland E. Kontermann et al.   DRUG DISCOVERY TODAY

Targeting key dioxygenases in tryptophan–kynurenine metabolism for immunomodulation and cancer chemotherapy

(2015) Christopher J.D. Austin et al.   DRUG DISCOVERY TODAY

Antigen-specific T cell therapies for cancer: Figure 1.

(2015) Teresa Manzo et al.   HUMAN MOLECULAR GENETICS

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

(2015) Sanja Stevanović et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

The interaction of anticancer therapies with tumor-associated macrophages

(2015) Alberto Mantovani et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Suppression of cancer relapse and metastasis by inhibiting cancer stemness

(2015) Youzhi Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Is the Tumor Infiltrating Natural Killer Cell (NK-TILs) Count in Infiltrating Ductal Carcinoma of Breast Prognostically Significant?

(2014) Ankita Singh Rathore et al.   Asian Pacific Journal of Cancer Prevention

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Engineered T cells for cancer therapy

(2014) Carl H. June et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense

(2014) Kayluz Frias Boligan et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The PD-1/PD-Ls pathway and autoimmune diseases

(2014) Suya Dai et al.   CELLULAR IMMUNOLOGY

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Infusions of Allogeneic Natural Killer Cells as Cancer Therapy

(2014) W. Leung   CLINICAL CANCER RESEARCH

Programmed death-1 pathway in cancer and autoimmunity

(2014) Ariel Pedoeem et al.   CLINICAL IMMUNOLOGY

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Regulatory T cells in cancer immunotherapy

(2014) Hiroyoshi Nishikawa et al.   CURRENT OPINION IN IMMUNOLOGY

Effect of tumor cells and tumor microenvironment on NK-cell function

(2014) Massimo Vitale et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy

(2014) Simone Muenst et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

(2014) S. D. Brown et al.   GENOME RESEARCH

Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma

(2014) Kirsten Kübler et al.   GYNECOLOGIC ONCOLOGY

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial

(2014) S. Riihijarvi et al.   HAEMATOLOGICA

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Shaping the repertoire of tumor-infiltrating effector and regulatory T cells

(2014) Peter A. Savage et al.   IMMUNOLOGICAL REVIEWS

Human Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications

(2014) Lorenzo Moretta et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Lectin Galactoside-binding Soluble 3 Binding Protein (LGALS3BP) Is a Tumor-associated Immunomodulatory Ligand for CD33-related Siglecs

(2014) Heinz Läubli et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance

(2014) Camilla Jandus et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis

(2014) Antonino Bruno et al.   JNCI-Journal of the National Cancer Institute

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

The self-obsession of T cells: how TCR signaling thresholds affect fate 'decisions' and effector function

(2014) Kristin A Hogquist et al.   NATURE IMMUNOLOGY

Therapeutic vaccines for cancer: an overview of clinical trials

(2014) Ignacio Melero et al.   Nature Reviews Clinical Oncology

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Value of Tumor-Infiltrating FoxP3+ T Cells in Gastrointestinal Cancers: A Meta Analysis

(2014) Yong Huang et al.   PLoS One

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer

(2014) Heinz Läubli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A red meat-derived glycan promotes inflammation and cancer progression

(2014) Annie N. Samraj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Clinical utility of natural killer cells in cancer therapy and transplantation

(2014) David A. Knorr et al.   SEMINARS IN IMMUNOLOGY

High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis

(2014) Zhong-Yu Yuan et al.   OncoTargets and Therapy

Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment

(2014) Theerawut Chanmee et al.   Cancers

Perspectives on Reprograming Cancer-Associated Dendritic Cells for Anti-Tumor Therapies

(2014) Fabian Benencia et al.   Frontiers in Oncology

Targeting Apoptosis Pathways for New Cancer Therapeutics

(2013) Longchuan Bai et al.   Annual Review of Medicine

Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions

(2013) J. Matta et al.   BLOOD

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium

(2013) Anna Bachmayr-Heyda et al.   BMC CANCER

Cancer Immunosurveillance and Immunoediting by Natural Killer Cells

(2013) Emilie Gross et al.   CANCER JOURNAL

Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin

(2013) R. Remark et al.   CLINICAL CANCER RESEARCH

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Response

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

(2013) M. J. Besser et al.   CLINICAL CANCER RESEARCH

Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas

(2013) S. Muenst et al.   DISEASE MARKERS

Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC

(2013) Mirna Balsamo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

(2013) Lára Hannesdóttir et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Tumor associated macrophages and neutrophils in cancer

(2013) Maria Rosaria Galdiero et al.   IMMUNOBIOLOGY

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

(2013) Fernando Ulloa-Montoya et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

(2013) Li Shi et al.   Journal of Hematology & Oncology

Human NK Cells Selective Targeting of Colon Cancer-Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules

(2013) R. Tallerico et al.   JOURNAL OF IMMUNOLOGY

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients’ survival

(2013) Maya Gulubova et al.   JOURNAL OF MOLECULAR HISTOLOGY

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

The immune system and inflammation in breast cancer

(2013) Xinguo Jiang et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion

(2013) Jason E Hudak et al.   Nature Chemical Biology

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer

(2013) Claudia C. Preston et al.   PLoS One

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

(2013) D. Sugiyama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

(2013) A. G. Chapuis et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Tumoricidal activity of human dendritic cells

(2013) Jurjen Tel et al.   TRENDS IN IMMUNOLOGY

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) R. Dummer et al.   ANNALS OF ONCOLOGY

Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers

(2012) M Stern et al.   BONE MARROW TRANSPLANTATION

Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective

(2012) D. T. Le et al.   CANCER RESEARCH

NK cell MHC class I specific receptors (KIR): from biology to clinical intervention

(2012) Ariane Thielens et al.   CURRENT OPINION IN IMMUNOLOGY

Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor

(2012) Mirna Balsamo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer

(2012) Gabriel A. Rabinovich et al.   IMMUNITY

Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study

(2012) Jeffrey M. Hardacre et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma

(2012) Shari Pilon-Thomas et al.   JOURNAL OF IMMUNOTHERAPY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma

(2012) Lisa M. Ebert et al.   PLoS One

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

(2011) Brian T. Fife et al.   Annals of the New York Academy of Sciences

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™

(2011) Theo Nicholaou et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

High transforming growth factor β expression represents an important prognostic parameter for surgically resected non–small cell lung cancer

(2011) William Sterlacci et al.   HUMAN PATHOLOGY

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

(2011) Bernhard Mlecnik et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Refined Prognostic Role of CD68-Positive Tumor Macrophages in the Context of the Cellular Micromilieu of Classical Hodgkin Lymphoma

(2011) Alexandar Tzankov et al.   PATHOBIOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion

(2010) Michele W.L. Teng et al.   CANCER RESEARCH

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

(2010) Y. Zhao et al.   CANCER RESEARCH

Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer

(2010) Zhengbin Shen et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

High-dose Interleukin-2 Can Produce a High Rate of Response and Durable Remissions in Appropriately Selected Patients With Metastatic Renal Cancer

(2010) Alaaeldin Shablak et al.   JOURNAL OF IMMUNOTHERAPY

Jekyll and Hyde: the role of the microenvironment on the progression of cancer

(2010) Michael Allen et al.   JOURNAL OF PATHOLOGY

Transmission of donor melanoma by organ transplantation

(2010) Dirk C Strauss et al.   LANCET ONCOLOGY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Sipuleucel-T

(2010) Celestia S. Higano et al.   NATURE REVIEWS DRUG DISCOVERY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selectins promote tumor metastasis

(2010) Heinz Läubli et al.   SEMINARS IN CANCER BIOLOGY

New views on natural killer cell-based immunotherapy for melanoma treatment

(2010) Shannon Burke et al.   TRENDS IN IMMUNOLOGY

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Combination therapy ofin vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma

(2009) Naoki Kunii et al.   CANCER SCIENCE

Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells

(2009) Ofer Fainaru et al.   FASEB JOURNAL

Regulatory T cells: how do they suppress immune responses?

(2009) S. Sakaguchi et al.   INTERNATIONAL IMMUNOLOGY

In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer

(2009) Franck Pagès et al.   JOURNAL OF CLINICAL ONCOLOGY

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

(2008) Ninke Leffers et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer

(2008) K. I. Al-Shibli et al.   CLINICAL CANCER RESEARCH

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma

(2008) A. Tzankov et al.   HAEMATOLOGICA

Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia

(2008) Luc Xerri et al.   HUMAN PATHOLOGY

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

(2008) Alexander MM Eggermont et al.   LANCET

Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target

(2008) Sandra D Bohling et al.   MODERN PATHOLOGY

Natural killer cell–directed therapies: moving from unexpected results to successful strategies

(2008) Magali Terme et al.   NATURE IMMUNOLOGY

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

(2008) Naomi N. Hunder et al.   NEW ENGLAND JOURNAL OF MEDICINE